Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL482689 | 1.00 | LMNA (0.39) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Ammonia Solution, Strong SCHEMBL4744785 | 1.00 | LMNA (0.39) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL92768 | 0.98 | LMNA (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL540415 | 0.98 | LMNA (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL2015790 | 0.98 | LMNA (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL215095 | 0.98 | LMNA (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL14808559 | 0.96 | LMNA (0.39) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL7068618 | 0.93 | LMNA (0.37) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL7144047 | 0.93 | LMNA (0.37) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL3864585 | 0.93 | LMNA (0.37) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686671-A2 | N-ACETYLHEXOSAMINE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS | Momenta Pharmaceuticals, Inc. (US) | 2014-01-22 | — | — | EP | claimed |
| WO-2012125553-A2 | N-ACETYLHEXOSAMINE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS | MOMENTA PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | WO | claimed |
| EP-2686671-A2 | N-ACETYLHEXOSAMINE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS | Momenta Pharmaceuticals, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012125553-A2 | N-ACETYLHEXOSAMINE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS | MOMENTA PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2011078893-A1 | DERIVATIVES OF APF AND METHODS OF USE | THE UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-06-30 | — | — | WO | disclosed |
| EP-2115460-A1 | NOVEL CARBOHYDRATE FROM HUMAN CELLS AND METHODS FOR ANALYSIS AND MODIFICATION THEREOF | Suomen Punainen Risti, Veripalvelu (FI) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008087258-A1 | NOVEL CARBOHYDRATE FROM HUMAN CELLS AND METHODS FOR ANALYSIS AND MODIFICATION THEREOF | SUOMEN PUNAINEN RISTI, VERIPALVELU (FI) | 2008-07-24 | — | — | WO | disclosed |